市場調査レポート

商品コード

1458160

ワクチンアジュバントの世界市場規模、シェア、成長分析：タイプ別、投与経路別 - 産業予測（2024～2031年）

Global Vaccine Adjuvants Market Size, Share, Growth Analysis, By Type(Pathogen-Based Adjuvants and Particulate Adjuvants), By Route of Administration(Intramuscular Route, and Intradermal Route) - Industry Forecast 2024-2031

出版日: 2024年03月27日 | 発行: SkyQuest

| ページ情報: 英文 219 Pages | 納期: 3～5営業日

価格

PDF & Excel (Single User License)

USD 5,300 836,870円

レポートPDF・Excelを1 名様のみがご利用頂けるライセンスです。PDF・Excell内のテキスト等のコピーは可能です。PDF・Excelの印刷は可能ですが、印刷したもののご利用はPDF・Excelのご利用範囲に準拠します

PDF & Excel (Multiple User License)

USD 6,200 978,980円

レポートPDF・Excel2-5名様までがご利用頂けるライセンスです。PDF・Excel内のテキスト等のコピーは可能です。PDF・Excelの印刷は可能ですが、印刷したもののご利用はPDF・Excelのご利用範囲に準拠します。

PDF & Excel (Enterprise License)

USD 7,100 1,121,090円

レポートPDF・Excelを同一企業に所属の全世界の方にご使用頂けるライセンスです。PDF・Excel内のテキスト等のコピーは可能です。PDF・Excelの印刷は可能ですが、印刷したもののご利用はPDF・Excelのご利用範囲に準拠します。

価格表記: USDを日本円(税抜)に換算

本日の銀行送金レート: 1USD=157.90円

全表示
概要
目次

概要

サンプル依頼リストに入れる

世界のワクチンアジュバントの市場規模は、2022年に8億9,323万米ドルとなり、2023年の10億1,819万米ドルから、2031年までには29億245万米ドルに成長し、予測期間中（2024～2031年）のCAGRは13.99％で成長する見通しです。

高齢者と肥満者の増加は、ワクチンアジュバント市場の成長を促進する主な要因の1つです。ヘルスケアインフラへの投資の増加がワクチンアジュバントの需要を促進しています。ワクチンアジュバント市場の魅力的な成長見通しに寄与するその他の副次的要因としては、技術革新、水酸化アルミニウムをベースとするアジュバントの改良、個人の可処分所得が挙げられます。新興国や低開発国における不利な償還シナリオに起因する技術的障害は、ワクチンアジュバント市場の拡大を妨げると思われます。規制当局の承認プロセスの長期化と厳しい規制遵守基準は、ワクチンアジュバント市場の成長率をさらに阻害すると予想されています。市場の成長ペースはアジュバントの副作用によってさらに鈍化すると思われます。これらの薬剤の製造コストが高いことも市場成長の障壁となると考えられています。

技術分析
価格分析
サプライチェーン分析
バリューチェーン分析
市場のエコシステム
IP分析
貿易分析
スタートアップ分析
原材料の分析
イノベーションマトリクス
パイプライン製品の分析
マクロ経済指標
主な投資の分析
主な成功要因
競合の程度

市場力学と見通し

市場力学
- 促進要因
- 機会
- 抑制要因
- 課題
規制情勢
ポーターの分析
将来の混乱についての特別な考察

ワクチンアジュバントの世界市場：タイプ別

市場概要
病原体ベースのアジュバント・粒子状アジュバント

ワクチンアジュバントの世界市場：投与経路別

市場概要
筋肉内投与
皮内投与

ワクチンアジュバントの世界市場規模：地域別

市場概要
北米
- 米国
- カナダ
欧州
- ドイツ
- スペイン
- フランス
- 英国
- その他欧州地域
アジア太平洋
- 中国
- インド
- 日本
- 韓国
- その他アジア太平洋
ラテンアメリカ
- ブラジル
- その他ラテンアメリカ地域
中東・アフリカ（MEA）
- GCC諸国
- 南アフリカ
- その他中東・アフリカ地域

競合情勢

上位5社の比較
主要企業の市場ポジショニング（2021年）
主な市場企業が採用した戦略
主要成功戦略
市場における最近の活動
主要企業の市場シェア（2021年）

主要企業プロファイル

CSL Limited（Australia）
GlaxoSmithKline plc（United Kingdom）
Novavax, Inc.（US）
SEPPIC（France）
Agenus Inc.（US）
InvivoGen（US）
Brenntag Biosector（Denmark）
Avanti Polar Lipids, Inc.（US）
Vaxine Pty Ltd.（Australia）
SPI Pharma（US）
OZ Biosciences（France）
CureVac AG（Germany）
Adjuvatis（France）
Advanced BioAdjuvants Corporation（US）
Adjuvance Technologies Inc.（US）
SDA Bio（Italy）
Bio Products Laboratory Ltd.（United Kingdom）
GSK Vaccines GmbH（Germany）
Mucosis B.V.（Netherlands）
NanoBio Corporation（US）

Product Code: SQMIG35I2155

Global Vaccine Adjuvants Market size was valued at USD 893.23 million in 2022 and is poised to grow from USD 1018.19 million in 2023 to USD 2902.45 million by 2031, growing at a CAGR of 13.99% during the forecast period (2024-2031).

The growing number of elderly and obese people is one of the main factors propelling the vaccine adjuvants market's growth. Growing investments in healthcare infrastructure are driving the demand for vaccination adjuvants. Additional secondary factors that will contribute to the vaccination adjuvant market's attractive growth prospects are technological innovations, improvements in adjuvants based on aluminum hydroxide, and individual disposable income. Technical obstacles resulting from the unfavorable reimbursement scenario in developing and underdeveloped nations would impede the expansion of the vaccine adjuvants market. Prolonged regulatory approval processes and strict regulatory compliance criteria would further impede the vaccine adjuvant market growth rate. The market's growth pace will be further slowed by adjuvant side effects. The high manufacturing costs of these medications will also be a barrier in the growth of the market.

Top-down and bottom-up approaches were used to estimate and validate the size of the Global Vaccine Adjuvants Market and to estimate the size of various other dependent submarkets. The research methodology used to estimate the market size includes the following details: The key players in the market were identified through secondary research, and their market shares in the respective regions were determined through primary and secondary research. This entire procedure includes the study of the annual and financial reports of the top market players and extensive interviews for key insights from industry leaders such as CEOs, VPs, directors, and marketing executives. All percentage shares split, and breakdowns were determined using secondary sources and verified through Primary sources. All possible parameters that affect the markets covered in this research study have been accounted for, viewed in extensive detail, verified through primary research, and analyzed to get the final quantitative and qualitative data.

Global Vaccine Adjuvants Market Segmental Analysis

Global Vaccine Adjuvants market is segmented on the basis of Product Type, Route of Administration, Diseases, Application, and region. By Product Type, the market is segmented into Adjuvant Emulsions, Pathogen Components, Particulate Adjuvants, Combination Adjuvants, and others. By Route of Administration, the market is segmented into Oral, Intramuscular, Intranasal, Subcutaneous, Intradermal, Others. By Diseases, the market is segmented into Cancer, Infectious Diseases, Others. By Application, the market is segmented into Research, and Commercial. The market is segmented into North America, Europe, Asia Pacific, Middle East and Africa, and Latin America as according region.

Drivers of the Global Vaccine Adjuvants Market

Because infectious diseases are becoming more common, it is expected that the global market for vaccine adjuvants would grow faster than average over the course of the forecast period. Immunization, for example, is one of the best ways to avoid infectious diseases. Globally, only COVID-19 claims more lives than tuberculosis (TB), which is still a major health risk because of drug-resistant TB strains. The World Health Organization (WHO) reports that over 1.6 million people died from tuberculosis (TB) in 2021.

Restraints in the Global Vaccine Adjuvants Market

The high toxicity and adverse effects of vaccination adjuvants are expected to impede the growth of the global vaccine adjuvants market. As per the CDC, adjuvanted vaccines have the potential to cause increased local symptoms like swelling, redness, and discomfort at the injection site, as well as increased systemic reactions including fever, body aches, and chills, as compared to non-adjuvanted vaccines. The adjuvants have a range of mild to severe side effects and can also occasionally cause adverse outcomes.

Market Trends of the Global Vaccine Adjuvants Market

The primary drivers of the global vaccine adjuvants market are the increased prevalence of allergies and infectious illnesses like cancer, HIV/AIDS, human papillomavirus (HPV), and tuberculosis. The current demand for innovative therapies for deadly diseases that are on the rise has led to the development of vaccinations with long-lasting effects on immunization. Currently undergoing clinical studies include AS01, ISCOM & ISCOMMATRIX, and AS02, which are examples of novel adjuvants developed by significant manufacturers. Governments from several countries are also advancing adjuvant technologies for human usage and vaccination programs. They are also concentrating on enhancing the healthcare system and obtaining funding for the investigation and development of new treatments.

Executive Summary

Market Overview
Wheel of Fortune

Research Methodology

Information Procurement
Secondary & Primary Data Sources
Market Size Estimation
Market Assumptions & Limitations

Parent Market Analysis

Market Overview
Market Size
Market Dynamics
- Drivers
- Opportunities
- Restraints
- Challenges

Key Market Insights

Technology Analysis
Pricing Analysis
Supply Chain Analysis
Value Chain Analysis
Ecosystem of the Market
IP Analysis
Trade Analysis
Startup Analysis
Raw Material Analysis
Innovation Matrix
Pipeline Product Analysis
Macroeconomic Indicators
Top Investment Analysis
Key Success Factor
Degree of Competition

Market Dynamics & Outlook

Market Dynamics
- Drivers
- Opportunities
- Restraints
- Challenges
Regulatory Landscape
Porters Analysis
- Competitive rivalry
- Threat of Substitute Products
- Bargaining Power of Buyers
- Threat of New Entrants
- Bargaining Power of Suppliers
Skyquest Special Insights on Future Disruptions
- Political Impact
- Economic Impact
- Social Impact
- Technical Impact
- Environmental Impact
- Legal Impact

Global Vaccine Adjuvants Market by Type

Market Overview
Pathogen-Based Adjuvants and Particulate Adjuvants

Global Vaccine Adjuvants Market by Route of Administration

Market Overview
Intramuscular Route
and Intradermal Route

Global Vaccine Adjuvants Market Size by Region

Market Overview
North America
- USA
- Canada
Europe
- Germany
- Spain
- France
- UK
- Rest of Europe
Asia Pacific
- China
- India
- Japan
- South Korea
- Rest of Asia-Pacific
Latin America
- Brazil
- Rest of Latin America
Middle East & Africa (MEA)
- GCC Countries
- South Africa
- Rest of MEA

Competitive Landscape

Top 5 Player Comparison
Market Positioning of Key Players, 2021
Strategies Adopted by Key Market Players
Top Winning Strategies
- By Development
- By Company
- By Year
Recent Activities in the Market
Key Companies Market Share (%), 2021

Key Company Profiles

CSL Limited (Australia)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
GlaxoSmithKline plc (United Kingdom)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Novavax, Inc. (US)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
SEPPIC (France)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Agenus Inc. (US)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
InvivoGen (US)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Brenntag Biosector (Denmark)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Avanti Polar Lipids, Inc. (US)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Vaxine Pty Ltd. (Australia)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
SPI Pharma (US)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
OZ Biosciences (France)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
CureVac AG (Germany)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Adjuvatis (France)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Advanced BioAdjuvants Corporation (US)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Adjuvance Technologies Inc. (US)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
SDA Bio (Italy)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Bio Products Laboratory Ltd. (United Kingdom)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
GSK Vaccines GmbH (Germany)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Mucosis B.V. (Netherlands)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
NanoBio Corporation (US)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments